Search Results - "Antin, Joseph H."

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation by Armand, Philippe, Kim, Haesook T., Logan, Brent R., Wang, Zhiwei, Alyea, Edwin P., Kalaycio, Matt E., Maziarz, Richard T., Antin, Joseph H., Soiffer, Robert J., Weisdorf, Daniel J., Rizzo, J. Douglas, Horowitz, Mary M., Saber, Wael

“…Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able…”
Get full text

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy by Maurer, Katie, Antin, Joseph H

“…Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many hematologic malignancies as well as non-malignant…”
Get full text

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial by Fuchs, Ephraim J., O’Donnell, Paul V., Eapen, Mary, Logan, Brent, Antin, Joseph H., Dawson, Peter, Devine, Steven, Horowitz, Mary M., Horwitz, Mitchell E., Karanes, Chatchada, Leifer, Eric, Magenau, John M., McGuirk, Joseph P., Morris, Lawrence E., Rezvani, Andrew R., Jones, Richard J., Brunstein, Claudio G.

“…Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB) or bone marrow (BM) from HLA-haploidentical relatives provided…”
Get full text

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure by Richardson, Paul G., Riches, Marcie L., Kernan, Nancy A., Brochstein, Joel A., Mineishi, Shin, Termuhlen, Amanda M., Arai, Sally, Grupp, Stephan A., Guinan, Eva C., Martin, Paul L., Steinbach, Gideon, Krishnan, Amrita, Nemecek, Eneida R., Giralt, Sergio, Rodriguez, Tulio, Duerst, Reggie, Doyle, John, Antin, Joseph H., Smith, Angela, Lehmann, Leslie, Champlin, Richard, Gillio, Alfred, Bajwa, Rajinder, D’Agostino Sr, Ralph B., Massaro, Joseph, Warren, Diane, Miloslavsky, Maja, Hume, Robin L., Iacobelli, Massimo, Nejadnik, Bijan, Hannah, Alison L., Soiffer, Robert J.

“…Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem…”
Get full text

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy by Kollman, Craig, Spellman, Stephen R., Zhang, Mei-Jie, Hassebroek, Anna, Anasetti, Claudio, Antin, Joseph H., Champlin, Richard E., Confer, Dennis L., DiPersio, John F., Fernandez-Viña, Marcelo, Hartzman, Robert J., Horowitz, Mary M., Hurley, Carolyn K., Karanes, Chatchada, Maiers, Martin, Mueller, Carlheinz R., Perales, Miguel-Angel, Setterholm, Michelle, Woolfrey, Ann E., Yu, Neng, Eapen, Mary

“…There are >24 million registered adult donors, and the numbers of unrelated donor transplantations are increasing. The optimal strategy for prioritizing among…”
Get full text

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma by Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Labussière Wallet, Hélène, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., Armand, Philippe

“…Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many…”
Get full text

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation by Gibson, Christopher J, Kim, Haesook T, Zhao, Lin, Murdock, H Moses, Hambley, Bryan, Ogata, Alana, Madero-Marroquin, Rafael, Wang, Shiyu, Green, Lisa, Fleharty, Mark, Dougan, Tyler, Cheng, Chi-An, Blumenstiel, Brendan, Cibulskis, Carrie, Tsuji, Junko, Duran, Madeleine, Gocke, Christopher D, Antin, Joseph H, Nikiforow, Sarah, DeZern, Amy E, Chen, Yi-Bin, Ho, Vincent T, Jones, Richard J, Lennon, Niall J, Walt, David R, Ritz, Jerome, Soiffer, Robert J, Gondek, Lukasz P, Lindsley, R Coleman

“…Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors…”
Get full text

Ocular Graft-versus-Host Disease: A Review by Shikari, Hasanain, MD, DNB, Antin, Joseph H., MD, Dana, Reza, MD, MSc, MPH

“…Abstract Graft-versus-host disease (GVHD) is a common cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Systemic…”
Get full text

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease by Koreth, John, Kim, Haesook T., Jones, Kyle T., Lange, Paulina B., Reynolds, Carol G., Chammas, Marie J., Dusenbury, Katherine, Whangbo, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Chen, Yi-Bin, Avigan, David, Blazar, Bruce R., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J.

“…Chronic graft-versus-host disease (cGVHD) is associated with inadequate reconstitution of tolerogenic CD4+CD25+FOXP3+ regulatory T cells (Tregs). Previous…”
Get full text

Risk factors for acute GVHD and survival after hematopoietic cell transplantation by Jagasia, Madan, Arora, Mukta, Flowers, Mary E.D., Chao, Nelson J., McCarthy, Philip L., Cutler, Corey S., Urbano-Ispizua, Alvaro, Pavletic, Steven Z., Haagenson, Michael D., Zhang, Mei-Jie, Antin, Joseph H., Bolwell, Brian J., Bredeson, Christopher, Cahn, Jean-Yves, Cairo, Mitchell, Gale, Robert Peter, Gupta, Vikas, Lee, Stephanie J., Litzow, Mark, Weisdorf, Daniel J., Horowitz, Mary M., Hahn, Theresa

“…Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell…”
Get full text

A disease risk index for patients undergoing allogeneic stem cell transplantation by Armand, Philippe, Gibson, Christopher J., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., Ritz, Jerome, Sorror, Mohamed L., Lee, Stephanie J., Deeg, H. Joachim, Storer, Barry E., Appelbaum, Frederick R., Antin, Joseph H., Soiffer, Robert J., Kim, Haesook T.

“…The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT…”
Get full text

ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death by Vander Lugt, Mark T, Braun, Thomas M, Hanash, Samir, Ritz, Jerome, Ho, Vincent T, Antin, Joseph H, Zhang, Qing, Wong, Chee-Hong, Wang, Hong, Chin, Alice, Gomez, Aurélie, Harris, Andrew C, Levine, John E, Choi, Sung W, Couriel, Daniel, Reddy, Pavan, Ferrara, James L.M, Paczesny, Sophie

“…Serum levels of an interleukin-1 receptor family member called suppressor of tumorigenicity 2 (ST2) predict response to therapy for graft-versus-host disease…”
Get full text

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT by Cutler, Corey, Logan, Brent, Nakamura, Ryotaro, Johnston, Laura, Choi, Sung, Porter, David, Hogan, William J., Pasquini, Marcelo, MacMillan, Margaret L., Hsu, Jack W., Waller, Edmund K., Grupp, Stephan, McCarthy, Philip, Wu, Juan, Hu, Zhen-Huan, Carter, Shelly L., Horowitz, Mary M., Antin, Joseph H.

“…Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of matched, related donor (MRD) allogeneic hematopoietic cell transplantation…”
Get full text

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial by Pidala, Joseph, Hamadani, Mehdi, Dawson, Peter, Martens, Michael, Alousi, Amin M., Jagasia, Madan, Efebera, Yvonne A., Chhabra, Saurabh, Pusic, Iskra, Holtan, Shernan G., Ferrara, James L.M., Levine, John E., Mielcarek, Marco, Anasetti, Claudio, Antin, Joseph H., Bolaños-Meade, Javier, Howard, Alan, Logan, Brent R., Leifer, Eric S., Pritchard, Theresa S., Horowitz, Mary M., MacMillan, Margaret L.

“…Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity…”
Get full text

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation by Cutler, Corey, Multani, Pratik, Robbins, David, Kim, Haesook T., Le, Thuy, Hoggatt, Jonathan, Pelus, Louis M., Desponts, Caroline, Chen, Yi-Bin, Rezner, Betsy, Armand, Philippe, Koreth, John, Glotzbecker, Brett, Ho, Vincent T., Alyea, Edwin, Isom, Marlisa, Kao, Grace, Armant, Myriam, Silberstein, Leslie, Hu, Peirong, Soiffer, Robert J., Scadden, David T., Ritz, Jerome, Goessling, Wolfram, North, Trista E., Mendlein, John, Ballen, Karen, Zon, Leonard I., Antin, Joseph H., Shoemaker, Daniel D.

“…Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid…”
Get full text

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism by Flynn, Ryan, Paz, Katelyn, Du, Jing, Reichenbach, Dawn K., Taylor, Patricia A., Panoskaltsis-Mortari, Angela, Vulic, Ante, Luznik, Leo, MacDonald, Kelli K.P., Hill, Geoffrey R., Nyuydzefe, Melanie S., Weiss, Jonathan M., Chen, Wei, Trzeciak, Alissa, Serody, Jon S., Aguilar, Ethan G., Murphy, William J., Maillard, Ivan, Munn, David, Koreth, John, Cutler, Corey S., Antin, Joseph H., Ritz, Jerome, Waksal, Samuel D., Zanin-Zhorov, Alexandra, Blazar, Bruce R.

“…Chronic graft-versus-host disease (cGVHD) remains a major complication following allogeneic bone marrow transplantation (BMT). The discovery of novel…”
Get full text

Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient by Larocca, Cecilia, Shanmugam, Vignesh, Zemmour, David, Antin, Joseph H., Lane, Andrew A.

Get full text

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans by Srinivasan, Mathangi, Flynn, Ryan, Price, Andrew, Ranger, Ann, Browning, Jeffrey L., Taylor, Patricia A., Ritz, Jerome, Antin, Joseph H., Murphy, William J., Luznik, Leo, Shlomchik, Mark J., Panoskaltsis-Mortari, Angela, Blazar, Bruce R.

“…Chronic GVHD (cGVHD) poses a significant risk for HSCT patients. Preclinical development of new therapeutic modalities has been hindered by models with…”
Get full text

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation by Armand, Philippe, Kim, Haesook T., Cutler, Corey S., Ho, Vincent T., Koreth, John, Alyea, Edwin P., Soiffer, Robert J., Antin, Joseph H.

“…Iron overload could be a significant contributor to treatment-related mortality (TRM) for patients with hematologic malignancies undergoing hematopoietic stem…”
Get full text

Long-term health outcomes of allogeneic hematopoietic stem cell transplantation by Kelkar, Amar H, Antin, Joseph H, Shapiro, Roman M

“…Fifty years of hematopoietic cell transplantation (HCT) has ushered in an exciting era of cellular therapy and has led to enormous progress in improving the…”
Get full text